Alumis Increases Stake in ACELYRIN Merger
Deal News | Apr 21, 2025 | Globenewswire
Alumis Inc. and ACELYRIN, Inc. have announced an amendment to their merger agreement which increases the ownership percentage of ACELYRIN stockholders in the combined company to 48%. This revision comes in response to market conditions and is aimed at maximizing value for ACELYRIN stakeholders. The merger, which has been approved by both companies’ boards, is designed to enhance financial flexibility and advance the combined pipeline of products in immunology. The companies, both based in California, plan to complete the merger in Q2 2025. Morgan Stanley and Guggenheim Securities are advising on the transaction.
Sectors
- Biopharmaceuticals
- Mergers & Acquisitions
Geography
- United States – Both companies, Alumis and ACELYRIN, are based in California, influencing the geographic relevance of this merger.
Industry
- Biopharmaceuticals – The article focuses on the biopharmaceutical industry with an emphasis on the development and potential merger of two companies, Alumis and ACELYRIN, focused on immunology and transformative medicines.
- Mergers & Acquisitions – This sector is highlighted due to the merger agreement between Alumis and ACELYRIN, which represents a strategic acquisition within the biopharmaceutical industry.
Financials
- 52% – Percentage of ownership in the combined company allotted to Alumis stockholders after the merger.
- 48% – Percentage of ownership in the combined company allotted to ACELYRIN stockholders after the merger.
- $737 million – Pro forma cash position of the combined company as of December 31, 2024.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Alumis Inc. | Target Company | Company | A clinical-stage biopharmaceutical company developing therapies using a precision approach for immune-mediated diseases. |
| ACELYRIN, Inc. | Selling Company | Company | A late-stage clinical biopharma company focused on immunology and the development of transformative medicines. |
| Morgan Stanley & Co. LLC | Financial Advisor to Alumis | Company | Investment banking firm advising Alumis on the financial aspects of the merger. |
| Guggenheim Securities, LLC | Financial Advisor to ACELYRIN | Company | Investment banking firm advising ACELYRIN on the financial aspects of the merger. |
| Cooley LLP | Legal Counsel to Alumis | Company | Law firm providing legal services to Alumis for the merger. |
| Fenwick & West LLP | Legal Counsel to ACELYRIN | Company | Law firm representing ACELYRIN for the legal proceedings related to the merger. |
| Paul Hastings LLP | Legal Counsel to ACELYRIN | Company | Law firm assisting ACELYRIN with legalities of the merger process. |